08:40 uur 25-06-2019

Aesyra SA kondigt sluiting aan van eerste financieringsronde in ontwikkeling AesyBite™, een nieuw tandheelkundig product dat bruxisme monitort en actief vermindert

LAUSANNE, Zwitserland–(BUSINESS WIRE)–Aesyra SA is een privaat bedrijf met hoofdzetel in Lausanne (Zwitserland) dat een medisch apparaat ontwikkelt dat in staat is om slaapbruxisme (nocturne-tandenknarsen) nauwkeurig te controleren en te verlichten. Slaapbruxisme is een zeer veel voorkomende aandoening waar nog geen therapie voor bestaat. De aandoening heeft een grote impact op het leven van de patiënt en wordt geassocieerd met ernstige slaapstoornissen zoals slaapapneu. Aesyra SA heeft het IP-adres al verkregen, prototypen ontwikkeld en klinische gegevens verzameld.

Marco Letizia (CEO) merkte op: “We zijn erg blij dat we de eerste financiering van VitaTech hebben gekregen om de industrialisatie, de klinische validatie en de commercialisering van onze technologie na te streven. Het feit dat Dr. Paolo Orsatti lid wordt van ons bestuur, zal ons team aanzienlijk versterken dankzij zijn leiderschap en ervaring in de MedTech-industrie.”

Aesyra SA Announces Closing of First Financing Round to Develop AesyBite™, a novel Dental Product that Monitors and Actively Reduces Bruxism

LAUSANNE, Switzerland–(BUSINESS WIRE)– Aesyra SA is a private company based in Lausanne (Switzerland) that is developing a medical device able to accurately monitor and relieve sleep bruxism (nocturne teeth grinding), a highly prevalent condition without therapy that has negative impact on patient’s life and is associated with serious sleep disorders such as sleep apnea. The company has already secured the IP, developed prototypes and obtained clinical data.

Marco Letizia (CEO) commented: “We are very pleased to have secured the first funding from VitaTech that will allow to pursue the industrialization, the clinical validation and the commercialization of our technology. Having Dr. Paolo Orsatti joining our board will significantly strengthen our team thanks to his leadership and experience into the MedTech industry.”

Paolo Orsatti (Director VitaTech) added: “We are convinced that Aesyra solution has a very large potential because it addresses an unmet medical need, it can positively impact the quality of life of the patients and potentially prevent other sleep disorders. We are delighted of our fund’s second investment in Aesyra that fits perfectly into VitaTech’s strategy to invest in companies positioned at the convergence of Healthcare and Technology”.

About Aesyra

Aesyra is a MedTech company developing next generation solutions for the monitoring and treatment of sleep diseases. The technology developed by the company has several applications in dentistry and sleep medicine at various stages of development, all of which offer significant partnering opportunities. The company works in close collaboration with medical experts from the Clinique Universitaire de Médecine Dentaire de Genève (CUMD) and the top-ranked opinion leaders in bruxism, dental implantology and sleep medicine. Aesyra is a spin-off of the Laboratory of Life Sciences Electronics (Prof. Carlotta Guiducci) at the Ecole Polytechnique Fédérale de Lausanne (EPFL).

For more information, please visit: www.aesyra.com

About VitaTech SA

VitaTech invests in European early stage and growth-phase high-tech companies positioned at the convergence of healthcare and technology. VitaTech is funded by the Zambon Family and by other European ultra-high-net-worth private investors and family offices.

Contacts

Aesyra SA

Marco Letizia, PhD

CEO

+ 41-76-288-5542

EPFL Innovation Park, Building C

CH-1015 Lausanne

Switzerland

Check out our twitter: @NewsNovumpr